Search

Displaying results 4261 - 4270 of 8196 in total
  1. Drug

    AMG 108

    go.drugbank.com/drugs/DB05545
    Investigational

    AMG 108 was investigated for use as an antirheumatic agent.

  2. Drug

    Ceruletide

    go.drugbank.com/drugs/DB00403
    Approved

    Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain...

  3. Drug

    Alvocidib

    go.drugbank.com/drugs/DB03496
    Investigational

    Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer.

  4. Drug

    Lutetium Lu 177-DTPA-omburtamab

    go.drugbank.com/drugs/DB31015
    Investigational

    Lutetium Lu 177-DTPA-omburtamab is a radioimmunoconjugate made up of [omburtamab] conjugated with lutetium Lu 177 via the chelating agent of diethylenetriaminepentaacetic acid (DTPA).[L54566]

    Synonyms: Lutetium Lu 177-DTPA-omburtamab
  5. Drug

    DA-8031

    go.drugbank.com/drugs/DB19024
    Investigational

    DA-8031 is under investigation in clinical trial NCT01798667 (Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation).

  6. Drug

    Meclofenamic acid

    go.drugbank.com/drugs/DB00939
    ApprovedInvestigationalVet approved

    A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.

  7. Drug

    Human papillomavirus type 11 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10300
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

  8. Drug

    Human papillomavirus type 16 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10301
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

  9. Drug

    Human papillomavirus type 18 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10302
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

  10. Drug

    Nonacog beta pegol

    go.drugbank.com/drugs/DB13933
    ApprovedInvestigational

    It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation.

    Products: REFİXİA 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİNTOZ VE ÇÖZÜCÜ , 1 ADET FLAKON + 1 ADET ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR, REFİXİA 1000 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİNTOZ VE ÇÖZÜCÜ , 1 ADET FLAKON + 1 ADET ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR